QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
QQQ   359.75 (+1.36%)
AAPL   173.66 (+0.73%)
MSFT   318.96 (+1.77%)
META   305.58 (+1.54%)
GOOGL   135.24 (+2.12%)
AMZN   127.00 (+1.83%)
TSLA   261.16 (+5.93%)
NVDA   440.41 (+1.20%)
NIO   8.83 (+2.56%)
BABA   84.05 (-0.58%)
AMD   104.07 (+3.99%)
T   14.65 (-0.88%)
F   11.98 (-0.75%)
MU   68.11 (+0.41%)
CGC   0.75 (+10.25%)
GE   108.85 (+1.01%)
DIS   79.30 (-0.30%)
AMC   8.34 (+6.24%)
PFE   33.29 (-1.80%)
PYPL   58.57 (+2.22%)
NFLX   376.90 (+0.04%)
NASDAQ:ONCE

Spark Therapeutics (ONCE) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$113.57
▼
$113.57
50-Day Range
$110.05
▼
$113.57
52-Week Range
$34.53
▼
$114.20
Volume
8,720 shs
Average Volume
891,560 shs
Market Capitalization
$4.38 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

ONCE stock logo

About Spark Therapeutics (NASDAQ:ONCE) Stock

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.


ONCE Stock News Headlines

September 26, 2023 | finance.yahoo.com
Gene Therapy Market Size to Reach USD 35.1 Billion By 2032 CAGR: 16.4%. Report By DataHorizzon Research
September 14, 2023 | news.yahoo.com
Controversial park sign sparks divided reaction online: ‘I need a couple copies of this sign’
October 4, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
September 12, 2023 | yahoo.com
‘Pain Hustlers’ Review: Emily Blunt Dominates Netflix’s Simplistic Opioid Drama
September 8, 2023 | benzinga.com
EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers
September 5, 2023 | markets.businessinsider.com
Sernova Corporation Announces the Appointment of Cynthia Pussinen as CEO
September 1, 2023 | msn.com
FTSE 100 Live: London blue-chips climb amid big GDP revision, surprise jump in US unemployment
August 29, 2023 | benzinga.com
Spark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial Institute
October 4, 2023 | Chaikin Analytics (Ad)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
August 16, 2023 | msn.com
Jim Kenney 1,000 days in: The fine print of the Philly mayor’s promises
August 14, 2023 | usatoday.com
Capital One Spark Miles Card review 2023
July 27, 2023 | bizjournals.com
MD Anderson partners with newly financed biotech to target 'undruggable' cancers
July 14, 2023 | yahoo.com
Jake Owen Was Asked About Theories That Taylor Swift's 'Sparks Fly' Is About Him...
July 14, 2023 | msn.com
Jake Owen Was Asked About Theories That Taylor Swift's 'Sparks Fly' Is About Him
June 28, 2023 | msn.com
City's plan to remove 3rd Avenue cycle track sparks petition to save it
June 12, 2023 | yahoo.com
Watch Sparks perform a frenzied This Town Ain't Big Enough For Both Of Us in 1974
June 8, 2023 | thestreet.com
Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
June 7, 2023 | msn.com
Storm Oscar risks bringing thunderstorms to Stoke-on-Trent as temperatures to hit 24C
June 1, 2023 | marketwatch.com
Monopar Therapeutics Shares Rise 6% After New Data on Camsirubicin
June 1, 2023 | markets.businessinsider.com
Where Monopar Therapeutics Stands With Analysts
May 29, 2023 | msn.com
Sparks talk new album, ever-growing fanbase: "Our audiences are pretty accepting of eccentricities"
May 23, 2023 | tmcnet.com
Spark +AI launches: a new era for Spark arrives with AI-powered email which elevates your writing, and ignites productivity
May 22, 2023 | businessinsider.com
Meet Wall Street's rising stars of equity research, the ones to watch as the stock market faces one of its biggest challenges yet
May 9, 2023 | msn.com
How Guilt Made Redfall's Bloody Tom a True Monster
April 30, 2023 | msn.com
School is in session as Sparks begin training camp
April 27, 2023 | msn.com
Recovering the Gains Made in Africa Through Vaccinations [press release]
April 22, 2023 | thestreet.com
13 Companies to Watch From MIT's Smart 50 List, Including 4 Buys
See More Headlines
Receive ONCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spark Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONCE Company Calendar

Last Earnings
8/07/2018
Today
10/04/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCE
CUSIP
N/A
CIK
1609351
Web
www.sparktx.com
Phone
888-772-7560
Fax
N/A
Employees
368
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-78,820,000.00
Net Margins
-358.41%
Pretax Margin
N/A
Return on Equity
-59.10%
Return on Assets
-33.13%

Debt

Debt-to-Equity Ratio
0.35
Current Ratio
4.67
Quick Ratio
4.35

Sales & Book Value

Annual Sales
$64.72 million
Price / Sales
67.60
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$13.15 per share
Price / Book
8.64

Miscellaneous

Outstanding Shares
38,523,000
Free Float
N/A
Market Cap
$4.38 billion
Optionable
Optionable
Beta
2.05
Ten Starter Stocks For Beginners to Buy Now Cover
Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Jeffrey D. Marrazzo (Age 40)
    Co-Founder, CEO & Director
  • Dr. Katherine A. High (Age 67)
    Co-Founder, Pres, Head of R&D and Director
  • Mr. Stephen W. Webster (Age 58)
    Chief Financial Officer
  • Mr. Joseph W. La Barge Esq. (Age 48)
    J.D., Chief Legal Officer & Sec.
  • Mr. Daniel R. Faga (Age 39)
    Chief Bus. Officer

Key Competitors

View All Competitors













ONCE Stock - Frequently Asked Questions

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) issued its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to the consensus estimate of $29.44 million. Spark Therapeutics had a negative trailing twelve-month return on equity of 59.10% and a negative net margin of 358.41%.

What other stocks do shareholders of Spark Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), Netflix (NFLX), Pfizer (PFE) and

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $113.57.

How much money does Spark Therapeutics make?

Spark Therapeutics (NASDAQ:ONCE) has a market capitalization of $4.38 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

How many employees does Spark Therapeutics have?

The company employs 368 workers across the globe.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The official website for the company is www.sparktx.com. The biotechnology company can be reached via phone at 888-772-7560 or via email at investor@sparktx.com.

This page (NASDAQ:ONCE) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -